诺为泰（Novotech）：2024类风湿性关节炎：全球临床试验概况报告（英文版）（25页）.pdf

1、novotech-JANUARY 19,2024Rheumatoid Arthritis Global Clinical Trial LandscapeAsia-Pacific,led by China,accounted for 58%of RA trialsPoland and,Germany in Europe,and the United States in North America take the leadAsia-Pacific showcased quicker recruitment durations and faster patient recruitment rate

2、sThe Asia-Pacific region demonstrated consistent positive CAGR growth58%Rheumatoid arthritis is a chronic autoimmune condition causing joint pain,and swelling,primarily afecting knees,wrists,hands,and feet.Prominent drugs in this market include Humira,Enbrel,and RemicadeThe market for RA treatment i

3、s diverse,featuring products from companies like AbbVie Inc.,Amgen Inc.,and Astellas Pharma Inc.Ongoing research on epigenetic drugs,microRNAs,and gene editing technologies will have potential breakthroughs in the treatment of RA in the future.Didyouknow?Rheumatoid arthritis afects around 1%of the g

4、lobal population,impacting women at least twice as much as menIn 2020,RA afected 17.6 million worldwide,causing many deathsAt the regional level,East and South Asia were mostly afected.While at the national level,China and,India were heavily afectedBy 2050,global RA cases are estimated to reach 31.7

5、 millionThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of N

6、ovotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or d